Cytomegalovirus proctitis mimicking rectal cancer in an immunocompetent elderly patient: a case report
© Subbarao et al.; licensee BioMed Central Ltd. 2014
Received: 25 October 2013
Accepted: 27 October 2014
Published: 15 November 2014
Cytomegalovirus infection is associated with significant morbidity and mortality in immunocompromised patients, but its impact on immunocompetent patients is still poorly understood. Furthermore, there is increasing evidence implying that chronic infection may contribute to a heightened cardiovascular risk.
We describe the case of incidental diagnosis of Cytomegalovirus proctitis in an immune-competent white British elderly gentleman, admitted following a stroke and investigated for rectal cancer following the development of bloody diarrhoea and persistent systemic inflammatory response.
This raised some several interesting points; firstly that we must revise our approach to investigating the immunocompetent elderly patient, secondly, could chronic Cytomegalovirus infection have contributed to the presentation of stroke in this patient and lastly what are the existing evidence for treatment in this population? We use this opportunity to try and address some of these questions and feel that this would be of benefit to the wider audience.
We discuss the risk factors for disease in immune-competent patients and also a brief overview of the benefits of treatment in this population.
KeywordsCMV Colitis Cell-mediated immunity
Cytomegalovirus (CMV) infection is a recognised cause of significant morbidity and mortality in immunocompromised patients due to the inability to curb viral replication. The clinical manifestations and duration of symptoms that are seen appear to vary between susceptible groups . Conversely, its impact on immunocompetent patients is still poorly understood. In recent years, the definitions of immunocompetent have been questioned; in this case, we use the term immunocompetent to describe those who are not undergoing chemotherapy or infected with human immunodeficiency virus (HIV). However, we describe an elderly gentleman with multiple co-morbidities whom falls under the spectrum of a broader group of patients who do not have an intact cell-mediated immunity and are susceptible to opportunistic infections . This is becoming an increasing challenge for clinicians who are being faced with such scenarios: a lack of understanding of the pathology of CMV infection and age-related immune changes may lead to a delay in diagnosis and a potential need for treatment. This case highlights the need to be vigilant, especially in those who present with symptoms that are ‘outside the box’.
We present the case of a 79-year-old white British man on the Acute Stroke unit undergoing Stroke care following a recent left MCA territory Infarct. Past medical history included hypertension, uncontrolled type 2 diabetes and chronic kidney disease stage 3.
During the first few weeks of his admission, his stay was complicated by both an acute NSTEMI with a concomitant troponin-I rise of 4.9 ng/ml (reference levels: 0.0 – 0.04 ng/ml) and systemic inflammatory response. He was initially pyrexial and blood tests revealed a total white cell count (WCC) of 16.5 × 109/L (rising from 12×109/L on admission, neutrophils count 13.0×109/L) and a C-reactive protein (CRP) of 107 mg/L (from 56 mg/L on admission). He was managed conservatively with treatment that included dual anti-platelet therapy.
It was felt that the respiratory system could clinically represent the most likely source of infection although a chest radiogram did not show any consolidation. In view of raised inflammatory markers and ongoing pyrexia, the patient was treated empirically with piperacillin-tazobactam. A full septic screen, including, one set of blood cultures, sputum and urine sample were sent for microbiology culture, which essentially had no significant growth.
Cytomegalovirus (CMV) is a double stranded DNA virus, member of the herpesviridae family . It is a highly successful human pathogen, which may be, transmitted both vertically and horizontally without an obvious clinical affect on the host. Worldwide, it is estimated that the sero-prevalence of CMV infection is between 40-100% , with the largest numbers affecting those from Asia and Africa and high-risk populations. After the initial infection, CMV may persist in a state of latency; effective control of the virus is dependent on an intact CD4+ and CD8+ cell mediated immunity . However, there may still be intermittent asymptomatic viral shedding in both the urine and saliva of both immune-competent and immunocompromised individuals .
CMV may manifest itself at the time of the initial infection (primary infection) or at a later stage (secondary), which may be due to reactivation of the latent infection or re-infection via a new exogenous strain . In immunocompromised patients, the inability to control viral replication forms the cornerstone of the devastating disease manifestations that are seen. In contrast, the course run by those with a competent immune system can be more varied. Whilst the majority of those affected may be asymptomatic or present with a generalized mononucleosis-like syndrome, other clinical manifestations are not as infrequent as previously thought . The gastrointestinal tract is the most common site affected by CMV in immune-competent patients with a predilection for the colon and rectum . However, the term immunocompetent could be considered a misnomer in certain situations. Previous studies have shown that CMV colitis spontaneously resolves in patients <55 years . Conversely, specific groups such as diabetics, age ≥55 years, chronic renal failure, pregnancy and untreated non-haematological malignancy appear to adversely influence survival . It is known that all these conditions do have a modulatory affect on the immune system; for example, both aging and diabetes are associated with a decline in cell-mediated immunity and a dysregulation in the cytokine responses, which is reflected by the increase in the numbers of overall infections . In fact, age-associated dysregulation in the immunity (Immune-senescence) is becoming increasingly well characterised. Aging is associated with reduced pool of naïve T cells and CMV infection further compounds this, through expansion of CMV specific CD8+ and CD4+ memory T cells . Moreover, observational data shows that CMV sero-positivity increases the risk of cardiovascular death in individuals over the age of 65 years . Thus, whilst these groups of patients are not immunocompromised in the traditional sense, they certainly do not have a preserved immunity and should be investigated as such. As a testimony to this, our patient was indeed afflicted by a number of co-morbidities that would be altering his immune responses: advanced age, uncontrolled type 2 diabetes and renal impairment. If this gentleman was infected by the human immune-deficiency virus (HIV) and had presented with per-rectal bleeding, he would have had a CMV PCR performed immediately as part of routine investigations, especially in view of the abnormalities seen on the CT scan.
In this case, the diagnosis of CMV infection was an incidental finding, based on the presence of intranuclear inclusion bodies at the histological examination. These inclusions are known as owl’s eye bodies, which stain dark pink on haematoxylin and eosin stain . We also demonstrated the molecular amplification of the viral DNA within the tissue and a low level viraemia was seen several weeks after the onset of symptoms. We can speculate that in this case, CMV proctitis was due to a re-activation of a latent infection evidenced by the presence of IgG antibodies and absence of IgM. Whether the initial presentation arose as a consequence of systemic sepsis or whether there was a high CMV viraemia at the start of admission driving the sepsis like syndrome remains to be elucidated. The cytokine effects of sepsis driving CMV viraemia have previously been described; it is appears that the presence of pro-inflammatory cytokines, tumour necrosis factor-alpha (TNF-alpha) and interleukin (IL)-1 beta in the early stages of sepsis reactivate CMV from latency . Furthermore, the later stages of sepsis are characterized by immunosuppressant interleukins such as IL-10 and IL-4 . These are believed to be involved in CMV proliferation following reactivation. However, several courses of broad-spectrum antibiotics failed to completely control the systemic inflammatory response in this patient, suggesting that this might have been driven by a large CMV viraemia. A recent systematic review identifying the contribution of CMV to outcomes in the critical care unit showed that CMV infection occurred in 0-36% of critically ill patients and the risk of CMV infection was five-fold higher in those patients presenting with sepsis . A further question arising from this case is whether CMV itself was an independent driver of the stroke and myocardial infarction, rather than just a bystander. Several studies previously, have shown that uncontrolled viraemia in HIV-infected patients have a higher cardiovascular risk compared to patients with undetectable viral loads on anti-retroviral therapy . Similarly, in vitro studies have demonstrated that CMV directly invades endothelial cells and has potent procoagulant properties . There is no current causal link between CMV seroprevalence and atheroma formation. However, epidemiological evidence shows accelerated atherosclerosis in the presence of CMV in patients following cardiac transplantation .
By the time the diagnosis of CMV proctitis was reached, patient’s symptoms had subsided, therefore obviating the need for treatment. However, there are no randomized controlled trials examining the role for antivirals in this population, with limited evidence available. Whilst the incidence of CMV-related disease in the immunocompetent population may be increasing, many recover without intervention. It would therefore be impractical to conduct a large randomized trial establishing clinical efficacy and toxicity. We therefore advocate the use of antivirals in such patients on a named basis, balancing the risks and benefits of treatment.
This case highlights an unusual clinical presentation of CMV proctitis in a patient whom rectal cancer was initially top of the differential diagnosis. The endoscopic and radiological findings, which were finally attributed to CMV infection, mimicked a malignancy. Whilst exclusion of a cancerous lesion was clearly a priority, this lead to a delay in the diagnosis of the CMV infection. Moreover, the persistent systemic inflammatory response was likely to have been secondary to a chronic CMV viraemia rather than an overt bacterial sepsis; additionally we pose the question of whether an uncontrolled viraemia could have contributed to the initial stroke. We therefore suggest that a high index of suspicion is important for an early diagnosis and potential instigation of treatment.
Written informed consent was obtained from the patient’s next of kin (as the patient was elderly and neurologically impaired) for publication of this Case Report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Emery VC: Investigation of CMV disease in immunocompromised patients. J Clin Pathol. 2001, 54: 84-88. 10.1136/jcp.54.2.84.PubMedPubMed CentralView ArticleGoogle Scholar
- Rafailidis PI, Mourtzoukou EG, Varbobitis IC, Falagas ME: Severe cytomegalovirus infection in apparently immunocompetent patients: a systematic review. Virol J. 2008, 5: 47-10.1186/1743-422X-5-47.PubMedPubMed CentralView ArticleGoogle Scholar
- de la Hoz RE, Stephens G, Sherlock C: Diagnosis and treatment approaches of CMV infections in adult patients. J Clin Virol. 2002, 25 (Suppl 2): S1-S12.PubMedView ArticleGoogle Scholar
- Ho M: Epidemiology of cytomegalovirus infections. Rev Infect Dis. 1990, 12 (Suppl 7): S701-S710.PubMedView ArticleGoogle Scholar
- Cicin-Sain L, Brien JD, Uhrlaub JL, Drabig A, Marandu TF, Nikolich-Zugich J: Cytomegalovirus infection impairs immune responses and accentuates T-cell pool changes observed in mice with aging. PLoS Pathog. 2012, 8: e1002849-10.1371/journal.ppat.1002849.PubMedPubMed CentralView ArticleGoogle Scholar
- Goodgame RW: Gastrointestinal cytomegalovirus disease. Ann Intern Med. 1993, 119: 924-935. 10.7326/0003-4819-119-9-199311010-00010.PubMedView ArticleGoogle Scholar
- Galiatsatos P, Shrier I, Lamoureux E, Szilagyi A: Meta-analysis of outcome of cytomegalovirus colitis in immunocompetent hosts. Dig Dis Sci. 2005, 50: 609-616. 10.1007/s10620-005-2544-6.PubMedView ArticleGoogle Scholar
- Schmucker DL, Heyworth MF, Owen RL, Daniels CK: Impact of aging on gastrointestinal mucosal immunity. Dig Dis Sci. 1996, 41: 1183-1193. 10.1007/BF02088236.PubMedView ArticleGoogle Scholar
- Weinberger B, Lazuardi L, Weiskirchner I, Keller M, Neuner C, Fischer KH, Neuman B, Wurzner R, Grubeck-Loebenstein B: Healthy aging and latent infection with CMV lead to distinct changes in CD8+ and CD4+ T-cell subsets in the elderly. Hum Immunol. 2007, 68: 86-90. 10.1016/j.humimm.2006.10.019.PubMedView ArticleGoogle Scholar
- Savva GM, Pachnio A, Kaul B, Morgan K, Huppert FA, Brayne C, Moss PA, Ageing S, Medical Research Council Cognitive F: Cytomegalovirus infection is associated with increased mortality in the older population. Aging Cell. 2013, 12: 381-387. 10.1111/acel.12059.PubMedView ArticleGoogle Scholar
- Szary NM, Kuwajima VK, Jiang PP, Puli SR, Bragg JD, Bechtold ML: Cytomegalovirus colitis in an immunocompetent host: a case report and review of the literature. Int J Gastroenterol. 2007, 7: 1-Google Scholar
- Cook CH, Trgovcich J, Zimmerman PD, Zhang Y, Sedmak DD: Lipopolysaccharide, tumor necrosis factor alpha, or interleukin-1beta triggers reactivation of latent cytomegalovirus in immunocompetent mice. J Virol. 2006, 80: 9151-9158. 10.1128/JVI.00216-06.PubMedPubMed CentralView ArticleGoogle Scholar
- Zedtwitz-Liebenstein K, Jaksch P, Wulkersdorfer B, Friehs H, Pempelfort SD, Burgmann H, Frass M: Usefulness of interleukin-10 detection in lung transplant patients with human cytomegalovirus infection with respect to virus persistence. Transplantation. 2007, 84: 268-271. 10.1097/01.tp.0000267157.78945.9d.PubMedView ArticleGoogle Scholar
- Osawa R, Singh N: Cytomegalovirus infection in critically ill patients: a systematic review. Crit Care. 2009, 13: R68-10.1186/cc7875.PubMedPubMed CentralView ArticleGoogle Scholar
- Phillips AN, Carr A, Neuhaus J, Visnegarwala F, Prineas R, Burman WJ, Williams I, Drummond F, Duprez D, Belloso WH, Goebel FD, Grund B, Hatzakis A, Vera J, Lundgren JD: Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther. 2008, 13: 177-187.PubMedGoogle Scholar
- Squizzato A, Ageno W, Cattaneo A, Brumana N: A case report and literature review of portal vein thrombosis associated with cytomegalovirus infection in immunocompetent patients. Clin Infect Dis. 2007, 44: e13-e16. 10.1086/509641.PubMedView ArticleGoogle Scholar
- Danesh J, Collins R, Peto R: Chronic infections and coronary heart disease: is there a link?. Lancet. 1997, 350: 430-436. 10.1016/S0140-6736(97)03079-1.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.